Good news emerged Sunday from the American Society for Clinical Oncology’s annual meeting for glioma patients with a certain genetic alteration as Servier Pharmaceuticals reported vorasidenib significantly improved progression-free survival.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,